Verdiva Bio Starts Phase 1 Trial of Weekly Oral VRB-103
LONDON and SAN FRANCISCO, July 30, 2026 Verdiva Bio announced that the first patient has been dosed in a...
Amylin Receptor Agonist
Advertisement
Viking Therapeutics Launches Phase 1 Study of VK3019 for Weight Loss
SAN DIEGO, June 24, 2026 Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial evaluating...
Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
Novo Nordisk Reports Strong Phase 2 Zenagamtide Data
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, June 6, 2026 Novo Nordisk has announced positive results from a Phase 2 clinical...
Advertisement
